nephrectomy, histological type, number of prior therapies, NLR at baseline, and the occurrence of immune-related adverse events (irAE).
INTRODUCTION AND OBJECTIVES: von Hippel-Lindau (VHL)
disease is an autosomal-dominant, multi-organ, familial neoplastic syndrome. To date, studies about targeted therapy in Chinese patients associated with von Hippel-Lindau disease are limited. In this study, we aimed to evaluate the efficacy and safety of four different tyrosine kinase inhibitors in patients with VHL disease.
METHODS: In this retrospective study, patients who diagnosed with VHL disease and received targeted therapy were recruited from Peking University First Hospital. Clinical data were obtained through interviews with patients or living family members and review of medical records. Patients were treated with four different tyrosine kinase inhibitors, respectively, including sunitinib (n[12), sorafenib (n[11), axitinib (n[6) and pazopanib (n[3) . Assessments of clinical response and degrees of tumor changes were performed according to the Response Evaluation Criteria in Sold Tumor (RECIST). Diverse adverse events related to the treatment of tyrosine kinase inhibitors were evaluated.
RESULTS: From July 2009 to April 2018, 39 patients with genetically verified or clinical manifestations consistent with von HippelLindau disease, of whom 32 patients eligible to this study. The mean time of targeted therapy was 27.8 months (range 3-87 months) and mean follow-up time was 29.1AE26.2 months (range 3-93 months). According to RECIST, 8 (25%) of 32 patients showed partial response to therapy, 16 (50%) of 32 patients achieved with stable disease and eight patients progressed. Lesion sites response were observed in 11 (31%) of 36 renal cell carcinomas, three (23%) of 13 renal cysts, four (27%) of 15 pancreatic lesions and one (20%) of five central nervous system hemangioblastomas. The study showed that the sizes of RCC (P[0.00013), renal cyst (P[0.027) and pancreatic lesion (P[0.003) were significant decreased after targeted therapy. The most common side-effects observed in this study including handfoot syndrome, diarrhea, alopecia, back pain, thrombocytopenia and fatigue. Dosage reductions were needed in 13 patients and often occurred in the sunitinib and sorafenib treatment group. Treatmentrelated serious adverse reactions included peridental abscess, hyperbilirubinemia and one case appeared perforation of nasal septum due to epistaxis repeatedly.
CONCLUSIONS: Tyrosine kinase inhibitors are effective in von Hippel-Lindau disease with acceptable side-effects, which are favorable options for VHL patients. Further evaluation of TKIs in patients with VHL disease in larger prospective studies is warranted. 
MP25-09 EARLY FLARE-RESPONSE OF C-REACTIVE PROTEIN IS ASSOCIATED WITH EFFICACY OF NIVOLUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Shohei Fukuda*, Kazutaka Saito, Yosuke Yasuda, Tokyo, Japan; Takahiko Soma, Saitama, Japan; Masahiro Toide, Hiroshi Fukushima, Shingo Moriyama, Sho Uehara, Tokyo, Japan; Naotaka Fukui, Saitama, Japan; Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Tokyo, Japan; Yukio Kageyama, Saitama, Japan; Yasuhisa Fujii, Tokyo, Japan INTRODUCTION AND OBJECTIVES: C-reactive protein (CRP), a representative systemic inflammatory response, has been shown to be a potential biomarker for renal cell carcinoma (RCC). The dynamic change of CRP levels, CRP kinetics, is a predictive factor for survival of patients with metastatic RCC (mRCC) in the tyrosine kinase inhibitor (TKI) era. In this study, we investigated the impact of the early CRP kinetics on the efficacy of nivolumab in patients with mRCC.
METHODS: A total of 32 patients (25 males and 7 females) were treated with nivolumab for mRCC from 2016 to 2018 at our institutions. Patients were divided into three groups according to their early CRP kinetics ( Fig.1) : patients whose CRP levels had increased to more than double from baseline within 1 month after initiation of nivolumab (flare) and then decreased to a lower value than baseline within 3 months (CRP flare-responder), patients whose CRP levels decreased by !30% from baseline within 3 months without "flare" (CRP responder), and the remaining patients (non-CRP responder). Maximum tumor shrinkage and objective response rate were evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The association of the early CRP kinetics and radiological responses to nivolumab was assessed.
RESULTS: The median follow up period and number of administration cycles were 5 months (range 1-18) and 8 cycles (1-28), respectively. The median baseline CRP level was 30 mg/L (0.2-169). Among all patients, CRP flare-responders, CRP responders and non-CRP responders were 8 (25%), 12 (37.5%) and 12 (37.5%) patients, respectively. Nine patients (28%) died of mRCC. During the follow-up period, 6 (19%), 19 (59%) and 7 (22%) patients experienced partial response, stable disease and progressive disease, respectively. The maximum change in target lesion from baseline of CRP flareresponder, CRP-responder and non-CRP responder group were -35%, -8% and þ19% on average, respectively (p<0.001) (Fig. 2) . Objective response rates of these three groups were 63%, 8% and 0%, respectively (p[0.001). Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e345
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